We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+32.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$343M
AUM Growth
+$158M
Cap. Flow
+$103M
Cap. Flow %
29.91%
Top 10 Hldgs %
65.57%
Holding
72
New
18
Increased
24
Reduced
6
Closed
20

Top Buys

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$17.6M
2
AMRN
Amarin Corp
AMRN
+$14.4M
3
DHR icon
Danaher
DHR
+$12.8M
4
EHTH icon
eHealth
EHTH
+$11.1M
5
GSK icon
GSK
GSK
+$10.9M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$5.19M
2
MRK icon
Merck
MRK
+$3.53M
3
ZGNX
Zogenix, Inc.
ZGNX
+$3.24M
4
TSRO
TESARO, Inc.
TSRO
+$2.67M
5
ABT icon
Abbott
ABT
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 86.25%
2 Industrials 8.36%
3 Financials 3.65%
4 Miscellaneous 1.46%
5 Real Estate 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
51
PUT
Novavax
NVAX
$1.53B
$79.9K 0.02%
+7,255
New +$229K
CNCE
52
CALL
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$27.8K 0.01%
+2,300
New +$33.9K
ABT icon
53
Abbott
ABT
$195B
– –
-31,400
Closed -$2.27M
ELV icon
54
Elevance Health
ELV
$85.5B
– –
-2,300
Closed -$604K
FOLD
55
DELISTED
Amicus Therapeutics
FOLD
– –
-62,750
Closed -$601K
ILMN icon
56
Illumina
ILMN
$32.6B
– –
-5,292
Closed -$1.54M
LAB icon
57
Standard BioTools
LAB
$252M
– –
-50,455
Closed -$435K
MRK icon
58
Merck
MRK
$366B
– –
-47,998
Closed -$3.53M
NTRA icon
59
Natera
NTRA
$47B
– –
-39,539
Closed -$552K
PBYI icon
60
Puma Biotechnology
PBYI
$468M
– –
-42,301
Closed -$861K
QGEN icon
61
Qiagen
QGEN
$8.9B
– –
-52,151
Closed -$1.91M
SAGE
62
DELISTED
Sage Therapeutics
SAGE
– –
-8,271
Closed -$792K
VTRS icon
63
CALL
Viatris
VTRS
$18.8B
– –
-158,600
Closed -$4.35M
VTRS icon
64
Viatris
VTRS
$18.8B
– –
-55,000
Closed -$1.51M
OPNT
65
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
– –
-13,901
Closed -$201K
SPNE
66
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
– –
-15,459
Closed -$282K
CFMS
67
DELISTED
Conformis, Inc. Common Stock
CFMS
– –
-5,474
Closed -$49K
EPZM
68
DELISTED
Epizyme, Inc
EPZM
– –
-25,449
Closed -$157K
BSTC
69
DELISTED
BioSpecifics Technologies Corp.
BSTC
– –
-22,000
Closed -$1.33M
GHDX
70
DELISTED
Genomic Health, Inc.
GHDX
– –
-23,866
Closed -$1.54M
LOXO
71
DELISTED
Loxo Oncology, Inc
LOXO
– –
-10,000
Closed -$1.4M
TSRO
72
DELISTED
TESARO, Inc.
TSRO
– –
-36,000
Closed -$2.67M
1 2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Eversept Partners held 72 positions worth $343M, up 86% from $185M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eversept Partners deployed $103M of net new capital in Q1 2019, opening 18 new positions and adding to 24 existing holdings. Its largest new stake was NuVasive, Inc.: 330,601 shares worth $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Aerie Pharmaceuticals, an estimated $5.19M trimmed.

  • Eversept Partners's largest Q1 2019 buy was NuVasive, Inc.: 330,601 shares worth $18.8M.
  • Eversept Partners added most to Amarin Corp in Q1 2019, an estimated $14.4M increase.
  • Eversept Partners's biggest Q1 2019 reduction was Aerie Pharmaceuticals, cutting an estimated $5.19M.
  • Eversept Partners fully exited Merck in Q1 2019, selling an estimated $3.53M.
  • Eversept Partners's ten largest holdings make up 66% of its $343M portfolio in Q1 2019.
  • Eversept Partners opened 18 new positions and closed 20 in Q1 2019.
  • Eversept Partners's portfolio value rose 86% quarter-over-quarter to $343M.

Based on Eversept Partners's 13F filing for Q1 2019, filed 14 May 2019.